Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06280092 · ClinicalTrials.gov registry record · Early Phase 1
Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery
A Early Phase 1 study of Epilepsy, sponsored by Sanjeet S. Grewal.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06280092: Recruiting Early Phase 1 study of Epilepsy, sponsored by Sanjeet S. Grewal.
NCT06280092 is a Early Phase 1 study of Epilepsy that is actively recruiting participants, run by Sanjeet S. Grewal. The registered enrollment target is 5 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06280092, a Early Phase 1 study of Epilepsy, is actively recruiting participants, sponsored by Sanjeet S. Grewal.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a non-randomized, open label, phase 1 clinical trial to evaluate the fesibility and safety of intrathalamic delivery of MSCs during standard of care DBS surgery for epilepsy. Subjects will be screened at our outpatient clinic and interested qualified subjects will be consented and offered participation in this trial. Once consent has been obtained, patients will undergo a standard preoperative evaluation which includes baseline laboratory values and a high-definition MRI. Patients will then undergo a stereotactic procedure for bilateral thalamic implantation of DBS leads through the ClearPoint® system. After the thalamic target for DBS is identified, cells will be infused directly into the anterior nucleus of the thalamus previous to lead implantation. Patients will be followed in the outpatient setting for up to a year after therapy application. Surgical, clinical, and radiographic data will be obtained during these visits
Primary Outcome
To investigate the feasibility and safety of local delivery of AMSCs for epilepsy by measuring the incidence of AEs related to the study agent.
Conditions Studied
Interventions
- DRUG AMSCs
Study Locations (1)
Florida
- Mayo Clinic - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-12-23 |
| Est. Completion | 2026-03 |
| Phase | Early Phase 1 |
What NCT06280092 shows while recruiting
NCT06280092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which AMSCs is the first listed.
NCT06280092 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06280092 about?
NCT06280092 is a clinical study titled "Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery". This study is a non-randomized, open label, phase 1 clinical trial to evaluate the fesibility and safety of intrathalamic delivery of MSCs during standard of care DBS surgery for epilepsy. Subjects will be screened at our outpatient clinic and interested qualified subjects will be consented and off...
What is the current status of trial NCT06280092?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2024-12-23. Estimated completion is 2026-03.
What conditions does trial NCT06280092 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT06280092?
The interventions under investigation include: AMSCs (DRUG).
Who is sponsoring clinical trial NCT06280092?
This trial is sponsored by Sanjeet S. Grewal, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06280092 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06280092's enrollment target sits among peer trials
5 156th of 160 higher than 2 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacological Modulation of Brain Oscillations in Memory Processing
RECRUITING · Early Phase 1
-
Effect of Rose Odor Exposure on Ictal Apnea
RECRUITING · Early Phase 1
-
Localizing Epileptic Networks Using MRI and iEEG
RECRUITING · Early Phase 1
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
RECRUITING
-
SeizEAR Safety Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI